International Edition
Latest News
Health

MHRA Updates Gene Therapy Definitions After Consultation

MHRA updates gene therapy definitions The UK medicines regulator has published the outcome of its consultation on modernising the legal definition of gene therapy medicinal products, the MHRA announced on 19 November. The changes aim to capture synthetic…

MHRA Updates Gene Therapy Definitions After Consultation

MHRA updates gene therapy definitions

The UK medicines regulator has published the outcome of its consultation on modernising the legal definition of gene therapy medicinal products, the MHRA announced on 19 November.

The changes aim to capture synthetic gene therapies and genome-editing treatments that do not fit neatly within the existing advanced therapy medicinal product (ATMP) framework, the agency said. Legislation to implement the updated definitions will now be brought forward. On 18 November, the MHRA launched AdvanceGxP, a service offering developers of personalised medicines manufacturing and the use of robotics, automation and artificial intelligence earlier regulatory and quality advice. The initiative is backed by funding from the Office for Life Sciences and will operate with limited initial capacity while the approach is evaluated, the agency said. Also on 18 November, the US Food and Drug Administration introduced its Enhanced Approach for Sampling and Testing (EAST) programme.

The initiative combines modern screening techniques with traditional testing methods to expand quality monitoring across more therapeutic classes, manufacturers and geographical regions, the FDA said. Samples will be collected from retail pharmacies and wholesale distributors to assess identity, purity and potency. A day earlier, on 17 November, the FDA launched the Global Reliance Disclosure Programme (GRDP), allowing companies to obtain minimally redacted approval packages for sharing with foreign regulators.

The programme is initially limited to certain tentative approvals under the President’s Emergency Plan for AIDS Relief (PEPFAR), excluding tentatively approved abbreviated new drug applications, the agency said. Applicants must request participation within 10 calendar days of approval. The FDA plans to expand GRDP in January 2027 to cover all novel drug applications and biologics licence applications, with a further pathway for already approved products expected in early 2027.

About the author: Health Desk

Health Desk at Archynewsy.